Question 1

Does semaglutide work without intensive behavioral therapy?

Accepted Answer

Yes, but STEP-3 demonstrates that adding IBT raises the ceiling. STEP-1, which paired semaglutide 2.4 mg with only monthly lifestyle counseling, produced a mean 14.9% weight loss. STEP-3, which paired the same drug at the same dose with 30 dietitian visits, a 1000-1200 kcal/day meal-replacement low-calorie diet for the first 8 weeks, and a graded physical-activity prescription reaching 200 minutes per week, produced a mean 16.0% weight loss. The 1.1 percentage-point difference between trials is roughly the marginal contribution of high-intensity IBT on top of the drug. The placebo arms tell the same story in reverse: STEP-1 placebo lost 2.4% on monthly counseling, STEP-3 placebo lost 5.7% on the full IBT package.

Question 2

What counts as intensive behavioral therapy in STEP-3?

Accepted Answer

The STEP-3 IBT package was modeled on the CMS-covered IBT for Obesity benefit and on the Diabetes Prevention Program. It included 30 individual in-person counseling visits with a registered dietitian over 68 weeks (weekly during the first 8 weeks, then tapering), a portion-controlled low-calorie diet of 1000-1200 kcal/day using meal replacements for the first 8 weeks, transition to a 1200-1800 kcal/day conventional-food hypocaloric diet through week 68, and a physical-activity prescription that started at 100 minutes per week and increased by 25 minutes every 4 weeks to a target of 200 minutes per week of moderate-intensity activity. Both arms received the identical IBT protocol; only the injection differed.

Question 3

Does insurance require IBT alongside semaglutide?

Accepted Answer

Many commercial plans and most state Medicaid programs that cover GLP-1 therapy for chronic weight management cite STEP-3 (or its summary in the Wegovy FDA label) as the rationale for requiring concurrent enrollment in a structured lifestyle program. Typical prior-authorization criteria require documentation of a reduced-calorie diet, increased physical activity, and at least monthly visits with a clinician, dietitian, or behavioral coach. The level of intensity varies — few plans require the full 30-visit STEP-3 protocol — but the principle that semaglutide is approved as an adjunct to lifestyle, not as a substitute, traces directly back to this trial.

Question 4

Was IBT alone effective in STEP-3?

Accepted Answer

Yes. Participants randomized to placebo plus the full IBT package lost a mean 5.7% of body weight at week 68, with 47.6% achieving at least 5% loss, 27.0% achieving at least 10% loss, and 13.2% achieving at least 15% loss. Those are clinically meaningful outcomes by any modern obesity-medicine standard and are substantially better than the 2.4% mean placebo loss seen in STEP-1, where the placebo arm received only monthly counseling. STEP-3 confirms that high-intensity, structured behavioral therapy produces real weight loss on its own; the trial's contribution is showing that semaglutide adds to that result rather than replacing it.

Question 5

How does STEP-3 versus STEP-1 inform real-world expectations?

Accepted Answer

STEP-1 and STEP-3 bracket the lifestyle-intensity continuum a real-world patient might experience. STEP-1, with monthly counseling only, reported a mean 14.9% weight loss on semaglutide; STEP-3, with weekly-then-monthly dietitian visits and meal replacements, reported 16.0%. Real-world cohort studies of community semaglutide use (Gasoyan 2024 and others) typically report mean losses in the 5-10% range, well below either trial. The most plausible explanation is that real-world patients receive substantially less behavioral support and less consistent medication adherence than either STEP arm. STEP-3 is the upper-bound benchmark; STEP-1 is the realistic ceiling for routine clinical care; observational data is the floor.

Question 6

Why were both arms given IBT instead of a no-treatment control?

Accepted Answer

Designing a trial with a no-IBT control arm would have been ethically and methodologically problematic. The FDA requires that anti-obesity medications be tested as adjuncts to a reduced-calorie diet and increased physical activity, the standard-of-care baseline for obesity treatment. Withholding lifestyle counseling from a control arm in a 68-week trial of adults with obesity would have failed equipoise and produced results not applicable to real prescribing. By giving both arms identical high-intensity IBT, STEP-3 isolates the pharmacologic effect of semaglutide above and beyond maximal behavioral therapy, which is the question both regulators and payers actually need answered.

Endpoint	Treatment	Comparator	Difference
Body-weight reduction ≥5% at week 68 Nearly half of the placebo arm met the conventional 5% clinical threshold on IBT alone, demonstrating that the lifestyle program itself was effective and not a sham comparator.	86.6%	47.6%	P<0.001
Body-weight reduction ≥10% at week 68	75.3%	27.0%	P<0.001
Body-weight reduction ≥15% at week 68 More than half of the semaglutide arm crossed the 15% threshold that approaches the lower bound of sleeve-gastrectomy outcomes at one year.	55.8%	13.2%	P<0.001
Body-weight reduction ≥20% at week 68	35.7%	3.7%	P<0.001
Absolute body-weight change at week 68 (kg)	−16.8 kg	−6.2 kg	Estimated treatment difference approximately −10.6 kg
Waist-circumference change at week 68 (cm)	−14.6 cm	−6.3 cm	Estimated treatment difference −8.3 cm; P<0.001
Systolic blood pressure change at week 68 (mmHg)	−5.6 mmHg	−1.6 mmHg	Estimated treatment difference −3.9 mmHg
Diastolic blood pressure change at week 68 (mmHg)	−3.0 mmHg	−0.8 mmHg	Estimated treatment difference −2.2 mmHg
HbA1c change at week 68 (percentage points) Participants were non-diabetic at entry; the HbA1c shift reflects movement within normoglycemic and prediabetic ranges and is consistent with the prediabetes-regression signal seen in STEP-1.	−0.51	−0.27	Estimated treatment difference approximately −0.24 percentage points
Triglycerides change at week 68 (% from baseline)	−22.5%	−6.5%	—

Event	Treatment rate	Comparator rate
Any gastrointestinal disorder Highest pooled GI rate of any STEP trial, attributable to the intensive caloric restriction layered on top of the GLP-1 effect.	82.8%	63.2%
Nausea Most common AE; clustered during the 16-week dose-escalation phase and largely resolved by maintenance.	58.2%	22.1%
Constipation	36.9%	24.5%
Diarrhea	36.1%	22.1%
Vomiting	27.3%	10.8%
Gallbladder-related events Consistent with the cholelithiasis signal observed across GLP-1 obesity trials and tied to the rate of weight loss.	4.9%	1.5%
Serious adverse events (any)	9.1%	2.9%
Discontinuation due to gastrointestinal events Overall study-drug discontinuation was 5.9% on semaglutide vs 2.9% on placebo; no deaths and no cases of acute pancreatitis were reported.	3.4%	0%

STEP-3 trial deep-dive: semaglutide 2.4 mg plus intensive behavioral therapy (Wadden 2021 JAMA)

Primary endpoint

Secondary endpoints

Adverse events

Clinical significance

Frequently Asked Questions

References

Related trial deep-dives